

RESEARCH ARTICLE

Radiological findings in nontuberculous mycobacterial pulmonary diseases: A comparison between the *Mycobacterium avium* complex and the *Mycobacterium abscessus* complex

Hiroaki Nagano¹*, Takeshi Kinjo², Jiro Fujita², Tomoo Kishaba¹

1 Department of Respiratory Medicine, Okinawa Chubu Hospital, Okinawa, Japan, **2** Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan

* These authors contributed equally to this work.

* hiroakinoko322violin@gmail.com



OPEN ACCESS

Citation: Nagano H, Kinjo T, Fujita J, Kishaba T (2022) Radiological findings in nontuberculous mycobacterial pulmonary diseases: A comparison between the *Mycobacterium avium* complex and the *Mycobacterium abscessus* complex. PLoS ONE 17(7): e0271660. <https://doi.org/10.1371/journal.pone.0271660>

Editor: Thomas Byrd, The University of New Mexico School of Medicine, UNITED STATES

Received: December 23, 2021

Accepted: July 5, 2022

Published: July 21, 2022

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0271660>

Copyright: © 2022 Nagano et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Abstract

The *Mycobacterium abscessus* complex (MABC) comprises rapidly growing mycobacteria and has received increasing attention recently, with an increasing number of associated infections reported worldwide. However, the clinical features of MABC pulmonary disease (MABC-PD), especially in terms of the chest computed tomography (CT) findings, are not fully understood. Thus, this retrospective, cross-sectional study aimed to evaluate the clinical background and chest high-resolution CT (HRCT) findings of MABC-PD in comparison with those of *Mycobacterium avium* complex PD (MAC-PD). Accordingly, 36 patients with MABC-PD and 65 patients with MAC-PD (defined according to the American Thoracic Society criteria), who were newly diagnosed at four major hospitals in Okinawa (Japan) between January 2012 and December 2017, were analyzed. With respect to their clinical background, only cardiovascular diseases were significantly more common in patients with MABC-PD than in those with MAC-PD (38.9% vs. 18.5%, $p = 0.0245$). HRCT revealed a significantly higher incidence of low attenuation in patients with MABC-PD than in those with MAC-PD (63.9% vs. 10.8%, $p < 0.0001$). On analyzing only never-smokers (20 and 47 patients with MABC-PD and MAC-PD, respectively), this significant difference remained (65.0% vs. 8.5%, $p < 0.0001$), suggesting MABC infection itself caused low attenuation. In terms of the distribution of abnormal shadows, the involvement of the right lower, left upper, and left lower lobes was more common in patients with MABC-PD than in those with MAC-PD. Furthermore, the mean number of involved lung lobes was significantly higher in patients with MABC-PD than in those with MAC-PD (5.6 vs. 4.7, $p < 0.001$). Although further studies are needed, we assume that the aforementioned radiological features of MABC-PD are due to the high virulence of MABC.

Funding: The authors received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Nontuberculous mycobacteria (NTM) are acid-fast bacteria; they are ubiquitous and can cause a variety of infections in humans. NTM pulmonary disease (NTM-PD) is the most common form of NTM infection. Its incidence continues to increase worldwide; this is true even in Japan due to an increasingly aging population and an increased awareness of the disease [1–3]. NTM comprise approximately 200 species, and the treatment strategy differs by the species; therefore, the first step to care for patients with NTM-PD is the identification of the causative NTM species from respiratory specimens. NTM-PD is most commonly caused by *Mycobacterium avium* complex (MAC). Rapidly growing mycobacteria such as *M. fortuitum*, *M. chelonae*, and those from the *M. abscessus* complex (MABC) are uncommon pathogens of NTM-PD; however, MABC has been frequently identified as the causative pathogen in patients with NTM-PD in South Korea and Taiwan [3–6]. In 2017, our data suggested that Okinawa (located in the southernmost region of Japan) was also one of the rare regions where MABC was the predominant cause of NTM-PD [7]. Studies on the clinical features of MABC-PD are insufficient, and only a few small-scale studies have assessed the characteristic computed tomography (CT) findings of MABC-PD [8, 9]. In clinical settings, the identification of the causative NTM species from respiratory specimens often takes weeks or months; thus, understanding the patient's background and radiological features that are suggestive of the causative NTM species is important for managing NTM-PD. Accordingly, the aim of this study was to evaluate the clinical features, especially the high-resolution CT (HRCT) findings, specific to MABC-PD. This was accomplished by comparing patients with MABC-PD and those with MAC-PD; because MAC is the most common cause of NTM-PD worldwide, it is often used as a comparative control in NTM studies. The manuscript details the methodology undertaken to achieve the study aim, key findings obtained, and relevant discussion with respect to previous literature.

Materials and methods

Patients

In this study, we included patients who were newly diagnosed with MABC-PD (the MABC-PD group) or MAC-PD (the MAC-PD group) between January 2012 and December 2017 at the Okinawa Chubu Hospital (550 hospital beds), University of the Ryukyus Hospital (600 hospital beds), Okinawa Hokubu Hospital (327 hospital beds), and Naha City Hospital (470 hospital beds). The diagnosis was made in accordance with the American Thoracic Society criteria [10]. The patients' medical records were retrospectively reviewed to compare the clinical backgrounds and chest HRCT findings between the two groups.

The exclusion criteria were as follows: 1) patients with a history of infection with other NTM species, 2) patients co-infected with respiratory pathogens other than NTM at the time of HRCT, 3) patients receiving antimycobacterial treatment at the time of HRCT, 4) patients with severe lung destruction secondary to underlying lung diseases and in whom an appropriate evaluation of NTM-PD-associated lung abnormalities was deemed impossible, and 5) patients with a history of lobectomy, total pneumonectomy, and tracheostomy or those who underwent mechanical ventilation procedures.

For NTM identification, respiratory specimens were cultured on 2% Ogawa agar, and the bacterial colonies obtained were collected for species identification. Species identification was performed via a DNA-DNA hybridization method using a commercially available identification kit (Kyokuto Pharmaceutical Industrial Co., Ltd., Tokyo, Japan).

Chest HRCT evaluation

Chest HRCT scans taken on the day closest to the date of NTM diagnosis (1 year before and after diagnosis) were evaluated by two experienced chest physicians (Nagano and Kinjo). The radiological patterns of NTM-PD were classified into the following four types: nodular bronchiectatic (NB) type with cavity, NB type without cavity, fibro-cavitary (FC) type, and unclassified. The NB type was characterized by bilateral bronchiectasis with nodular infiltrates involving the middle lung zones, while the fibro-cavitary type was characterized by cavitary lesions typically located in the upper lobes [11, 12]. For each patient, the presence of patterns reflective of parenchymal abnormalities in the following six regions of the lung was recorded: right upper lobe, right middle lobe (RML), right lower lobe (RLL), left upper segment, left lingular segment (LLS), and left lower lobe (LLL). These patterns were based on previous reports [8, 9, 13, 14], and comprised the following: (1) centrilobular ground-glass opacity (GGO), (2) centrilobular nodules, (3) small nodules <10 mm, (4) nodules sized 10–29 mm, (5) tree-in-bud appearance, (6) volume loss, (7) cavity, (8) consolidation, (9) bronchiectasis, (10) low attenuation, (11) GGO, (12) linear scarring, and (13) calcification. Patients could present with more than one pattern.

Statistical analysis

Nominal and continuous variables were compared between the MABC-PD and MAC-PD groups using the Fisher's exact test and the Wilcoxon/Kruskal–Wallis test, respectively. A p value < 0.05 was considered significant. All data were analyzed with JMP pro 15 (SAS Institute Inc., North Carolina, USA).

Ethics

The Institutional Ethics Committee of the Okinawa Chubu Hospital approved this study (approval number: 2018–89). The need for informed consent from each patient for inclusion in this study was waived due to the study's retrospective nature. Even then, patients were given the opportunity to opt-out via the Okinawa Chubu Hospital's website.

Results

The MABC-PD and MAC-PD groups comprised 36 and 65 patients, respectively. MAC consisted of *M. avium* ($n = 16$, 24.6%) and *M. intracellulare* ($n = 49$, 75.4%). On comparing the background characteristics between the two groups, it was found that the incidence of cardiovascular disease was higher in the MABC-PD group than in the MAC-PD group (38.9% vs. 18.5%, $p = 0.025$; Table 1).

In terms of the HRCT findings, there were no significant differences between two groups regarding the NB type with cavity and FC type. However, the NB type without cavity was more common in the MAC-PD group than in the MABC-PD group (66.2% vs. 38.7%, $p = 0.008$). Conversely, the unclassified type was more common in the MABC-PD group than in the MAC-PD group (30.6% vs. 12.6%, $p = 0.0246$; Table 2).

Furthermore, low attenuation was observed more commonly in the MABC-PD group than in the MAC-PD group (63.9% vs. 10.8%, $p < 0.0001$). To exclude the effect of smoking, we analyzed the incidence of low attenuation among never-smokers (MABC-PD: 20 patients, MAC-PD: 47 patients). Accordingly, low attenuation was still found to be more common in the MABC-PD group than in the MAC-PD group (65.0% vs. 8.5%, $p < 0.0001$). In terms of the distribution of abnormal shadows, the involvement of the RLL, left upper segment, and LLL was more common in the MABC-PD group than in the MAC-PD group. Furthermore, the

Table 1. Patients' background characteristics.

	MABC-PD (n = 36)	MAC-PD (n = 65)	p value
Age (median, years)	77	78	0.2487
Male sex	17 (47.2%)	20 (30.8%)	0.1317
BMI (median, kg/m ²)	19.7	19.2	0.3815
Smoking history	14 (41.2%)	17 (26.6%)	0.1727
Comorbidities			
Interstitial lung disease	5 (13.9%)	5 (7.7%)	0.3225
Old healed tuberculosis	7 (19.4%)	8 (12.3%)	0.3867
COPD	7 (19.4%)	7 (10.8%)	0.2433
Bronchial asthma	8 (22.2%)	9 (13.9%)	0.4052
Gastroesophageal disease	4 (11.1%)	3 (4.6%)	0.2435
Lung cancer	1 (2.8%)	1 (1.5%)	1.0000
Other solid cancers	5 (13.9%)	6 (9.2%)	0.5152
Hematological cancer	2 (5.6%)	1 (1.5%)	0.2886
Cardiovascular diseases	14 (38.9%)	12 (18.5%)	0.0329
Chronic liver disease	5 (13.9%)	2 (3.1%)	0.0939
Chronic kidney disease	7 (19.4%)	11 (16.9%)	0.7898
Cerebrovascular disease	4 (11.1%)	13 (20.0%)	0.2842
Neuromuscular disease	1 (2.8%)	1 (1.5%)	1.0000
Autoimmune disease	4 (11.1%)	9 (13.8%)	0.7668
Diabetes mellitus	9 (25.0%)	7 (10.8%)	0.0869
Corticosteroid usage [#]	7 (19.4%)	10 (15.4%)	0.5921
Immunosuppressant usage	2 (5.6%)	2 (3.1%)	0.6149

[#] Patients receiving corticosteroid daily at any dose.

Abbreviations: MABC-PD, *Mycobacterium abscessus* complex-pulmonary disease; MAC-PD, *Mycobacterium avium* complex-pulmonary disease; COPD, chronic obstructive pulmonary disease; BMI; body mass index.

<https://doi.org/10.1371/journal.pone.0271660.t001>

mean number of involved lung lobes was significantly higher in the MABC-PD group than in the MAC-PD group (5.6 vs. 4.7, $p < 0.001$; Table 3).

Discussion

This study aimed to investigate the clinical features of MABC-PD by comparing them with those of MAC-PD. Although patients with NTM-PD co-infected with multiple NTM species have been described previously [15–17], the present study only included patients with NTM-PD who were infected with either MABC or MAC alone. Therefore, this study could compare the clinical features purely between MABC-PD and MAC-PD. Our data

Table 2. General classification of the imaging findings.

	MABC-PD (n = 36)	MAC-PD (n = 65)	p value
NB type with cavity	7 (19.4%)	9 (13.9%)	0.5710
NB type without cavity	14 (38.7%)	43 (66.2%)	0.0117
FC type	3 (8.3%)	5 (7.7%)	1.0000
Unclassified	11 (30.6%)	8 (12.6%)	0.0337

Abbreviations: MABC-PD, *Mycobacterium abscessus* complex-pulmonary disease; MAC-PD, *Mycobacterium avium* complex-pulmonary disease; NB, nodular bronchiectatic; FC; fibro-cavitary.

<https://doi.org/10.1371/journal.pone.0271660.t002>

Table 3. Detailed comparison of the imaging findings between the MABC-PD and MAC-PD groups.

Findings	MABC-PD (n = 36)	MAC-PD (n = 65)	p value
Centrilobular GGO	16 (44.4%)	28 (43.1)	1.0000
Centrilobular nodule	18 (50.0%)	33 (50.5%)	1.0000
Small nodule <10 mm	28 (77.8%)	58 (89.2%)	0.1484
Nodule of size 10–29 mm	10 (27.8%)	14 (21.5%)	0.4770
Tree-in-bud appearance	31 (86.1%)	47 (72.3%)	0.1409
Decreased volume	11 (30.6%)	32 (49.2%)	0.0930
Smooth-wall cavity	2 (5.6%)	5 (7.7%)	1.0000
Irregular-wall cavity	9 (25.0)	8 (16.8%)	0.1632
Consolidation	23 (63.9%)	45 (69.2%)	0.6596
Bronchiectasis	31 (86.1%)	59 (90.8%)	0.5152
Low attenuation	23 (63.9%)	7 (10.8%)	< 0.0001
GGO	20 (55.6%)	27 (41.5%)	0.2136
Linear opacity	32 (88.9%)	61 (93.9%)	0.4507
Calcification	12 (33.3%)	28 (43.1%)	0.3987
Involved lung area			
RUL	33 (91.7%)	55 (84.6%)	0.3699
RML	31 (86.1%)	54 (83.1%)	0.7820
RLL	36 (100%)	49 (75.4%)	0.0005
LUS	35 (97.2%)	47 (72.3%)	0.0014
LLS	33 (91.7%)	54 (83.1%)	0.3679
LLL	35 (97.2%)	50 (76.9%)	0.0088
Mean number of involved lung lobes/segments	5.6	4.7	0.0005

Abbreviations: MABC, *Mycobacterium abscessus* complex; MAC, *Mycobacterium avium* complex; GGO, ground glass opacity; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUS, left upper segment; LLS, left lingular segment; LLL, left lower lobe.

<https://doi.org/10.1371/journal.pone.0271660.t003>

demonstrated that cardiovascular diseases were more common in patients with MABC-PD than in those with MAC-PD. HRCT analysis revealed that low attenuation was significantly more common in MABC-PD than in MAC-PD; this significant difference was also noted among never-smokers. Additionally, the number of involved lung lobes was significantly higher in patients with MABC-PD than in those with MAC-PD.

Only few reports are available on an association between MABC and heart disease. Hsu et al. pointed out that patients with either cardiovascular diseases or risk factors for cardiovascular diseases (male sex and age ≥ 55 years) were 4.5 times more likely to have MABC-PD [18]. Moreover, the chronic inflammation associated with NTM-PD may induce a secondary cardiovascular disease [19]. Because the association between MABC and cardiovascular disease is not well understood, further studies are needed.

We first reported that low attenuation in the lungs is commonly seen in MABC-PD. This finding was persistent among never-smokers, indicating that MABC (and not smoking) might cause the low attenuation. No previously published reports have mentioned the relationship between MABC-PD and low attenuation. Kubo et al. analyzed CT findings obtained during the inspiration and expiration phases, and reported that air trapping occurred in the apical airways in MAC-PD [20, 21]. The authors indicated that lung function tests revealed air trapping-associated obstructive disorders in patients with MAC-PD. Although we did not perform CT during the inspiration and expiration phases, the low attenuation was considered to be an

important finding as it corresponded to air trapping on expiration [22]. Fujita et al. demonstrated that pathological findings (bronchiectasis and centrilobular nodules) in patients with MAC-PD indicated widespread lymphocyte infiltration and continuous epithelial cell infiltration from the bronchioles to the acinus, as well as the narrowing of the lumens of the bronchioles at various levels [23, 24]. These findings explained the obstructive respiratory dysfunction in patients with MAC-PD, which has been previously reported by Kubo et al. [20, 21]. There are few reports on the relationship between radiological findings and the pathology of MABC. However, by the same mechanisms as in MAC-PD, it is possible that intense inflammation in the airspace leads to a narrowing of the bronchiole lumen and air trapping in MABC-PD, which are then reflected as low attenuation on HRCT.

Findings from a typical case of low attenuation in MABC-PD are illustrated in Fig 1. The patient was a 63-year-old woman without prior lung infection or lung diseases. She had never smoked tobacco. Nevertheless, chest radiography revealed apparent diaphragm flattening and hyperinflation bilaterally (Fig 1A). Furthermore, chest HRCT revealed low-density areas in the lung parenchyma, despite no history of smoking or emphysema. In addition, this patient demonstrated multi-lobe involvement, including the right middle lobe, lingula, and bilateral lower lobes (arrows in Fig 1B and 1C).

Furthermore, the number of involved lung lobes was significantly higher in patients with MABC-PD than in those with MAC-PD. Although a few studies have compared the CT findings between MABC-PD and MAC-PD, there is no evidence that MABC-PD tends to involve more lung areas [8, 16]. Some studies reported that radiological imaging in MABC-PD revealed a more extensive distribution of abnormal patterns, including cavities, bronchial dilatation, and infiltration shadows [25, 26]. Fujita et al. reported that the RML and LLS are commonly involved in respiratory infections by MAC, and that centrilobular nodules and diffuse bronchiectasis are the characteristic radiological findings [23]. Our study demonstrated that




Fig 1. A typical case of low attenuation in MABC-PD. Chest radiograph (A) demonstrates bilateral diaphragm flattening and hyperinflation. Chest HRCT scans (B, C) reveal low-density areas in the lung parenchyma (oval enclosure mark); multi-lobe involvement with consolidation, bronchiectasis, and GGO (arrow) in the right middle lobe and LLS; and a tree-in-bud appearance and small centrilobular nodules in the RLL (arrowhead).

<https://doi.org/10.1371/journal.pone.0271660.g001>

not only the RML and LLS, but also the right upper lobe, RLL, and LLL were involved in patients with MABC-PD. According to Chung et al., no significant difference was observed in the presence of small nodules, the tree-in-bud pattern, and bronchiectasis between MABC-PD and MAC-PD [8]. However, nodules, airspace consolidation, and thin-wall cavities were observed more commonly in patients with MAC-PD. Harada et al. reported that the nodular bronchiectatic form was commonly associated with *M. abscessus* than with *M. massiliense* [27]. Victoria et al. reported that MABC could be rapidly progressive and lead to lung destruction in a short period of time [28]. Although further investigation is needed, it is possible that the intensity of MABC virulence is related to the extensive distribution of lung lesions.

Our study has some limitations. First, as a retrospective study conducted in several hospitals, our data are sparse and potentially biased. Second, we could not analyze MABC at the subspecies level (*M. abscessus* subsp. *abscessus*, *M. abscessus* subsp. *massiliense*, and *M. abscessus* subsp. *bolletii*) because we could not preserve the bacterial colonies cultured from patients with MABC-PD. Differentiation between the three subspecies of MABC may reveal more profound results.

Conclusions

Our data revealed that low attenuation and extensive lesions in the lungs on HRCT, possibly reflecting the high virulence of MABC, were more common in patients with MABC-PD than in those with MAC-PD. Understanding the radiological features of MABC-PD is important from a clinical perspective; thus, further radiological studies are needed to deepen our knowledge about MABC-PD.

Acknowledgments

The authors thank Mariko Teruya, Akiko Maeda, and Kazuhiko Matsuno for their contribution to data collection. The authors also thank Dr. Joel Branch and Editage (www.editage.com) for English language editing.

Author Contributions

Conceptualization: Hiroaki Nagano, Takeshi Kinjo, Jiro Fujita, Tomoo Kishaba.

Data curation: Hiroaki Nagano, Takeshi Kinjo.

Formal analysis: Takeshi Kinjo.

Investigation: Hiroaki Nagano.

Methodology: Hiroaki Nagano.

Project administration: Hiroaki Nagano.

Software: Takeshi Kinjo.

Supervision: Takeshi Kinjo, Jiro Fujita, Tomoo Kishaba.

Writing – original draft: Hiroaki Nagano.

Writing – review & editing: Hiroaki Nagano, Takeshi Kinjo, Jiro Fujita, Tomoo Kishaba.

References

1. Thomson RM. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. *Emerg Infect Dis.* 2010; 16: 1576–1583. <https://doi.org/10.3201/eid1610.091201> PMID: 20875283

2. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. *Am J Respir Crit Care Med*. 2012; 185: 881–886. <https://doi.org/10.1164/rccm.201111-2016OC> PMID: 22312016
3. Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, et al. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. *Emerg Infect Dis*. 2016; 22: 1116–1117. <https://doi.org/10.3201/eid2206.151086> PMID: 27191735
4. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. *Clin Chest Med*. 2015; 36: 13–34. <https://doi.org/10.1016/j.ccm.2014.10.002> PMID: 25676516
5. Simons S, van Ingen J, Hsueh PR, Van Hung N, Dekhuijzen PN, Boeree MJ, et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. *Emerg Infect Dis*. 2011; 17: 343–349. <https://doi.org/10.3201/eid1703.100604> PMID: 21392422
6. Wang CC, Lin MC, Liu JW, Wang YH. Nontuberculous mycobacterial lung disease in southern Taiwan. *Chang Gung Med J*. 2009; 32: 499–508. PMID: 19840507
7. Nagano H, Kinjo T, Nei Y, Yamashiro S, Fujita J, Kishaba T. Causative species of nontuberculous mycobacterial lung disease and comparative investigation on clinical features of *Mycobacterium abscessus* complex disease: a retrospective analysis for two major hospitals in a subtropical region of Japan. *PLoS ONE*. 2017; 12: e0186826. <https://doi.org/10.1371/journal.pone.0186826> PMID: 29059250
8. Chung MJ, Lee KS, Koh WJ, Lee JH, Kim TS, Kwon OJ, et al. Thin-section CT findings of nontuberculous mycobacterial pulmonary diseases: comparison between *Mycobacterium avium-intracellulare* complex and *Mycobacterium abscessus* infection. *J Korean Med Sci*. 2005; 20: 777–783. <https://doi.org/10.3346/jkms.2005.20.5.777> PMID: 16224151
9. Catherinot E, Roux AL, Vibet MA, Bellis G, Ravilly S, Lemonnier L, et al. *Mycobacterium avium* and *Mycobacterium abscessus* complex target distinct cystic fibrosis patient subpopulations. *J Cyst Fibros*. 2017; 12: 74–80. <https://doi.org/10.1016/j.jcf.2012.06.009> PMID: 22857820
10. Daley CL, Laccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. *Clin Infect Dis*. 2020; 71: e1–e36. <https://doi.org/10.1093/cid/ciaa241> PMID: 32628747
11. Jhun BW, Moon SM, Jeon K, Kwon OJ, Yoo H, Carriere KC, et al. Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study. *Eur Respir J*. 2020; 55: 1900798. <https://doi.org/10.1183/13993003.00798-2019> PMID: 31619468
12. Ikuyama Y, Ushiki A, Akahane J, Kosaka M, Kitaguchi Y, Urushihata K, et al. Comparison of clinical characteristics of patients with *Mycobacterium avium* complex disease by gender. *Epidemiol Infect*. 2019; 147: e108. <https://doi.org/10.1017/S0950268819000293> PMID: 30869034
13. Kim JS, Tanaka N, Newell JD, Degroote MA, Fulton K, Huit G, et al. Nontuberculous mycobacterial infection: CT scan findings, genotype, and treatment responsiveness. *Chest*. 2005; 128: 3863–3869. <https://doi.org/10.1378/chest.128.6.3863> PMID: 16354855
14. Kim HS, Lee KS, Koh WJ, Jeon K, Lee EJ, Kang H, et al. Serial CT findings of *Mycobacterium massiliense* pulmonary disease compared with *Mycobacterium abscessus* disease after treatment with antibiotic therapy. *Radiology*. 2012; 263: 260–270. <https://doi.org/10.1148/radiol.12111374> PMID: 22371609
15. Shin SH, Jhun BW, Kim SY, Choe J, Jeon K, Huh HJ, et al. Nontuberculous mycobacterial lung diseases caused by mixed infection with *Mycobacterium avium* complex and *Mycobacterium abscessus* complex. *Antimicrob Agents Chemother*. 2018; 62: e01105–e01118. <https://doi.org/10.1128/AAC.01105-18> PMID: 30104265
16. Joao I, Bujdaková H, Jordao L. Opportunist coinfections by nontuberculous mycobacteria and fungi in immunocompromised patients. *Antibiotics (Basel)*. 2020; 9: 771. <https://doi.org/10.3390/antibiotics9110771> PMID: 33147819
17. Griffith D, Phillely J, Elliott-Brown B, Sara S, Richard W. Isolation of *M. abscessus* from patients with *M. avium* complex (MAC) lung disease. *Eur Respir J*. 2013; 42: 4387.
18. Hsu JY, Cheng A, Ku CC, Chen YC, Wang JT, Hsieh TW, et al. *Mycobacterium abscessus* and *Mycobacterium massiliense* exhibit distinct host and organ specificity: a cross-sectional study. *Int J Infect Dis*. 2022; 116: 21–26. <https://doi.org/10.1016/j.ijid.2021.12.348> PMID: 34954310
19. Restrepo MI, Reyes LF. Pneumonia as a cardiovascular disease. *Respirology*. 2018; 23: 250–259. <https://doi.org/10.1111/resp.13233> PMID: 29325222
20. Kubo K, Yamazaki Y, Masubuchi T, Takamizawa A, Yamamoto H, Koizumi T, et al. Pulmonary infection with *Mycobacterium avium-intracellulare* leads to air trapping distal to the small airways. *Am J Respir Crit Care Med*. 1998; 158:979–984. <https://doi.org/10.1164/ajrccm.158.3.9802042> PMID: 9731034

21. Kubo K, Yamazaki Y, Hachiya T, Hayasaka M, Honda T, Hasegawa M, et al. *Mycobacterium avium*-intracellulare pulmonary infection in patients without known predisposing lung disease. *Lung*. 1998; 176: 381–391. <https://doi.org/10.1007/pl00007620> PMID: 9780296
22. Maycher B, O'Connor R, Long R. Computed tomographic abnormalities in *Mycobacterium avium* complex lung disease include the mosaic pattern of reduced lung attenuation. *Can Assoc Radiol J*. 2000; 51: 93–102. PMID: 10786917
23. Fujita J. Radiological findings of non-tuberculous mycobacteria respiratory infection. *Kekkaku*. 2003; 78: 557–561. PMID: 14509228
24. Fujita J, Ohtsuki Y, Suemitsu I, Shigeto E, Yamadori I, Obayashi Y, et al. Pathological and radiological changes in resected lung specimens in *Mycobacterium avium* intracellulare complex disease. *Eur Respir J*. 1999; 13: 535–540. <https://doi.org/10.1183/09031936.99.13353599> PMID: 10232422
25. Han D, Lee KS, Koh WJ, Yi CA, Kim TS, Kwon OJ. Radiographic and CT findings of nontuberculous mycobacterial pulmonary infection caused by *Mycobacterium abscessus*. *AJR Am J Roentgenol*. 2003; 181: 513–517. <https://doi.org/10.2214/ajr.181.2.1810513> PMID: 12876037
26. Kurashima A. Radiographic findings of pulmonary nontuberculous mycobacteriosis other than *Mycobacterium avium* complex. *Kekkaku*. 2009; 84: 577–583. PMID: 19764463
27. Harada T, Akiyama Y, Kurashima A, Nagai H, Tsuyuguchi K, Fujii T, et al. Clinical and microbiological differences between *Mycobacterium abscessus* and *Mycobacterium massiliense* lung diseases. *J Clin Microbiol*. 2012; 50: 3556–3561. <https://doi.org/10.1128/JCM.01175-12> PMID: 22915613
28. Victoria L, Gupta A, Gómez JL, Robledo J. *Mycobacterium abscessus* complex: a review of recent developments in an emerging pathogen. *Front Cell Infect Microbiol*. 2021; 11: 659997. <https://doi.org/10.3389/fcimb.2021.659997> PMID: 33981630